Recommended phase (Ph) II dose (RP2D) selection for investigational Aurora A kinase (AAK) inhibitor MLN8237 (Alisertib; A) combined with paclitaxel (P): Clinical pharmacokinetics (PK), drug-drug interaction (DDI) assessment, and translational exposure-efficacy modeling.
Karthik Venkatakrishnan
Employment or Leadership Position - Millennium
Xiaofei Zhou
Employment or Leadership Position - Millennium
Jeffrey Ecsedy
Employment or Leadership Position - Millennium
Jerome Mettetal
Employment or Leadership Position - Millennium
Ely Benaim
Employment or Leadership Position - Millennium
Stock Ownership - Millennium
Hua Liu
Employment or Leadership Position - Millennium
Gerald Steven Falchook
Research Funding - Millennium
Howard Fingert
Employment or Leadership Position - Millennium
Wen Chyi Shyu
Employment or Leadership Position - Millennium
Robert Kleinfield
Employment or Leadership Position - Millennium
Ashley Milton
Employment or Leadership Position - Millennium